News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
46,107 Results
Type
Article (1344)
Company Profile (3)
Press Release (44760)
Section
Business (17438)
Career Advice (99)
Deals (2332)
Drug Development (5418)
FDA (743)
Job Trends (880)
News (25393)
Policy (1450)
Tag
Academia (49)
Accelerated approval (2)
Allergies (7)
Alliances (1896)
ALS (15)
Alzheimer's disease (91)
Antibody-drug conjugate (ADC) (14)
Approvals (771)
Artificial intelligence (10)
Autoimmune disease (5)
Automation (1)
Bankruptcy (18)
Best Places to Work (778)
Biosimilars (4)
Bladder cancer (10)
Brain cancer (2)
Breast cancer (40)
Cancer (268)
Cardiovascular disease (35)
Career advice (84)
CAR-T (8)
Cell therapy (33)
Clinical research (4888)
Collaboration (30)
Compensation (22)
Complete response letters (1)
COVID-19 (66)
CRISPR (2)
C-suite (6)
Cystic fibrosis (6)
Data (472)
Depression (11)
Diabetes (32)
Diagnostics (303)
Digital health (1)
Drug discovery (4)
Drug pricing (3)
Duchenne muscular dystrophy (29)
Earnings (15003)
Events (6852)
Executive appointments (7)
FDA (1008)
Fibrodysplasia Ossificans Progressiva (1)
Funding (32)
Gene editing (5)
Gene therapy (15)
GLP-1 (45)
Government (99)
Grass and pollen (1)
Guidances (145)
Healthcare (859)
HIV (4)
Huntington's disease (2)
IgA nephropathy (8)
Immunology and inflammation (12)
Immuno-oncology (2)
Indications (7)
Infectious disease (84)
Inflammatory bowel disease (5)
Influenza (4)
Intellectual property (13)
Interviews (25)
IPO (1575)
Job creations (133)
Job search strategy (59)
Kidney cancer (1)
Labor market (2)
Layoffs (15)
Legal (283)
Liver cancer (6)
Lung cancer (28)
Lymphoma (31)
Machine learning (3)
Manufacturing (14)
MASH (6)
Medical device (743)
Medtech (748)
Mergers & acquisitions (765)
Metabolic disorders (59)
Multiple sclerosis (8)
Neurodegenerative disease (10)
Neuropsychiatric disorders (6)
Neuroscience (155)
NextGen: Class of 2026 (180)
Non-profit (80)
Now hiring (1)
Obesity (20)
Opinion (5)
Ovarian cancer (15)
Pain (2)
Pancreatic cancer (8)
Parkinson's disease (10)
Patents (35)
Patient recruitment (15)
Peanut (1)
People (1669)
Pharmaceutical (2)
Pharmacy benefit managers (2)
Phase 1 (1123)
Phase 2 (2031)
Phase 3 (1896)
Pipeline (718)
Policy (2)
Postmarket research (303)
Preclinical (517)
Prostate cancer (14)
Psychedelics (2)
Radiopharmaceuticals (17)
Rare diseases (48)
Real estate (192)
Regulatory (1241)
Reports (4)
Research institute (50)
Resumes & cover letters (19)
RNA editing (2)
RSV (6)
Schizophrenia (7)
Series A (7)
Series B (5)
Service/supplier (1)
Sickle cell disease (12)
Special edition (2)
Spinal muscular atrophy (2)
Startups (89)
Tariffs (1)
The Weekly (1)
Vaccines (42)
Venture capital (2)
Weight loss (9)
Women's health (3)
Date
Today (9)
Last 7 days (31)
Last 30 days (88)
Last 365 days (2101)
2026 (185)
2025 (2082)
2024 (2268)
2023 (2500)
2022 (4371)
2021 (3424)
2020 (2674)
2019 (2241)
2018 (1666)
2017 (1184)
2016 (982)
2015 (1329)
2014 (916)
2013 (532)
2012 (635)
2011 (742)
2010 (6779)
Location
Africa (24)
Alabama (2)
Arizona (14)
Asia (2863)
Australia (360)
California (681)
Canada (196)
China (41)
Colorado (36)
Connecticut (30)
Delaware (32)
Europe (5820)
Florida (132)
Georgia (31)
Idaho (1)
Illinois (74)
India (2)
Indiana (35)
Iowa (3)
Japan (37)
Kansas (5)
Kentucky (2)
Louisiana (7)
Maine (6)
Maryland (97)
Massachusetts (527)
Michigan (19)
Minnesota (32)
Missouri (6)
Montana (1)
Nevada (3)
New Hampshire (8)
New Jersey (298)
New York (166)
North Carolina (126)
Northern California (362)
Ohio (16)
Oklahoma (1)
Oregon (1)
Pennsylvania (168)
South America (59)
Southern California (274)
Tennessee (5)
Texas (96)
United States (2725)
Utah (29)
Virginia (10)
Washington D.C. (1)
Washington State (80)
Wisconsin (7)
46,107 Results for "121".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Complete response letters
REGENXBIO’s Hunter Syndrome Gene Therapy Fails To Win FDA Nod
The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission for the gene therapy RGX-121.
February 10, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
September 23, 2025
·
9 min read
Funding
Merida Enters Autoimmune and Allergy Arena With $121M Series A
Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing autoantibodies.
April 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases
April 8, 2025
·
4 min read
Drug Development
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prostate cancer (mCRPC).
June 5, 2024
·
1 min read
Press Releases
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 11, 2025
·
6 min read
BioCapital
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
June 18, 2024
·
9 min read
Press Releases
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 6, 2025
·
6 min read
Amgen-Backed Seismic Secures $121M in Series B Funding
Mass.-based Seismic Therapeutic secured a new investor in Bessemer Venture Partners and $121 million in its Series B round as it looks to push its two lead candidates into the clinic.
December 4, 2023
·
2 min read
·
Tyler Patchen
Drug Development
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
REGENXBIO Inc. (Nasdaq: RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II) demonstrating that the pivotal phase of the trial met its primary endpoint with statistical significance.
February 7, 2024
·
10 min read
1 of 4,611
Next
